NEW YORK (GenomeWeb) – Nanosphere said after the close of the market Monday that it has closed its public offering of 40 million shares of its common stock at $.50 per share.

The firm expects the offering to bring in net proceeds of approximately $18.4 million, which it will use for general corporate purposes and working capital.

Nanosphere noted that provided 400,000 shares of its common stock to the underwriters as part of the underwriters' fee. Chardan Capital Markets served as the sole book-running manager on the offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.